144 related articles for article (PubMed ID: 27142293)
1. Malignancy associated SIADH: Characterization and clinical implications.
Goldvaser H; Rozen-Zvi B; Yerushalmi R; Gafter-Gvili A; Lahav M; Shepshelovich D
Acta Oncol; 2016; 55(9-10):1190-1195. PubMed ID: 27142293
[TBL] [Abstract][Full Text] [Related]
2. The syndrome of inappropriate antidiuretic hormone secretion: Distribution and characterization according to etiologies.
Shepshelovich D; Leibovitch C; Klein A; Zoldan S; Milo G; Shochat T; Rozen-zvi B; Gafter-Gvili A; Lahav M
Eur J Intern Med; 2015 Dec; 26(10):819-24. PubMed ID: 26563934
[TBL] [Abstract][Full Text] [Related]
3. Yield of workup for patients with idiopathic presentation of the syndrome of inappropriate antidiuretic hormone secretion.
Shepshelovich D; Leibovitch C; Klein A; Zoldan S; Shochat T; Green H; Rozen-Zvi B; Lahav M; Gafter-Gvili A
Eur J Intern Med; 2016 Jul; 32():60-4. PubMed ID: 27016871
[TBL] [Abstract][Full Text] [Related]
4. [Is hyponatremia a prognostic marker of survival for lung cancer?].
Petereit C; Zaba O; Teber I; Grohé C
Pneumologie; 2011 Sep; 65(9):565-71. PubMed ID: 21837588
[TBL] [Abstract][Full Text] [Related]
5. Medication-induced SIADH: distribution and characterization according to medication class.
Shepshelovich D; Schechter A; Calvarysky B; Diker-Cohen T; Rozen-Zvi B; Gafter-Gvili A
Br J Clin Pharmacol; 2017 Aug; 83(8):1801-1807. PubMed ID: 28168757
[TBL] [Abstract][Full Text] [Related]
6. Etiology of postoperative hyponatremia following pediatric intracranial tumor surgery.
Williams CN; Riva-Cambrin J; Bratton SL
J Neurosurg Pediatr; 2016 Mar; 17(3):303-9. PubMed ID: 26613271
[TBL] [Abstract][Full Text] [Related]
7. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
8. Hyponatremia in cancer patients.
Platania M; Verzoni E; Vitali M
Tumori; 2015; 101(2):246-8. PubMed ID: 25908038
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
10. Apparent idiopathic hyponatremia in an ambulatory geriatric population.
Miller M; Hecker MS; Friedlander DA; Carter JM
J Am Geriatr Soc; 1996 Apr; 44(4):404-8. PubMed ID: 8636585
[TBL] [Abstract][Full Text] [Related]
11. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
Petereit C; Zaba O; Teber I; Lüders H; Grohé C
BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients.
Coussement J; Danguy C; Zouaoui-Boudjeltia K; Defrance P; Bankir L; Biston P; Piagnerelli M
Am J Nephrol; 2012; 35(3):265-70. PubMed ID: 22378162
[TBL] [Abstract][Full Text] [Related]
14. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH)--treatment with lithium.
Finsterer U; Beyer A; Jensen U; Wacker R; Kellermann W; Unertl K; Militzer H; Männer F; Weber R; Arnold P; Peter K
Intensive Care Med; 1982; 8(5):223-9. PubMed ID: 6813362
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia now--a goldmine or a dead end?
Gross P
Adv Clin Exp Med; 2012; 21(5):559-61. PubMed ID: 23356191
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
Dasta JF; Chiong JR; Christian R; Lin J
Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
[TBL] [Abstract][Full Text] [Related]
17. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
18. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
Bilgetekin I; Erturk I; Basal FB; Karacin C; Karadurmus N; Oksuzoglu B; Demirci U
Int Urol Nephrol; 2021 Feb; 53(2):301-307. PubMed ID: 32869173
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
[TBL] [Abstract][Full Text] [Related]
20. [Current considerations in syndrome of inappropriate secretion of antidiuretic hormone/syndrome of inappropriate antidiuresis].
Velasco Cano MV; Runkle de la Vega I
Endocrinol Nutr; 2010 May; 57 Suppl 2():22-9. PubMed ID: 21130959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
